ArticleOncoimmunology2013
Modifying tumor-associated macrophages: An important adjunct to immunotherapy.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer.Medical oncology (Northwood, London, England) · 2014Trial
- Macrophages as a "weapon" in anticancer cellular immunotherapy.The Kaohsiung journal of medical sciences · 2021Review
- Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics.JCI insight · 2019Article
- Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition.BMC research notes · 2019Article
- Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing.Oncotarget · 2018Article
- Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management.Human vaccines & immunotherapeutics · 2016Review
- Bladder cancer cells re-educate TAMs through lactate shuttling in the microfluidic cancer microenvironment.Oncotarget · 2015Article
- The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention.Translational lung cancer research · 2015Review
- Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Human vaccines & immunotherapeutics · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic success of immunotherapy requires specific alterations of the tumor microenvironment and/or the inhibition of tumor-elicited immunosuppression. Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment. We have recently shown that modulating TAMs dramatically augments the efficacy of immunotherapy. TAM-activating agents should hence be considered as an addition to immunotherapy in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.